Osimertinib: as the comparator
17 studies: what is tested is compared with it. Page 1 of 1. Open to participants first (12), then studies with results posted, then the rest; newest registration first within each.
- ASKC202 Plus Limertinib as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLCNot yet recruitingNCT07897188Phase 3Report a problem
- Therapy for Advanced NSCLC With EGFR 19delins MutationNot yet recruitingNCT07458919Early Phase 1Report a problem
- A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung CancerNot yet recruitingNCT07285148Phase 1/2Report a problem
- A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung CancerRecruitingNCT07229729Phase 2Report a problem
- Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon MutationsRecruitingNCT07185997Phase 3Report a problem
- Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)RecruitingNCT07079475Phase 1/2Report a problem
- A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain MetastasesRecruitingNCT06970639Phase 3Report a problem
- Aumolertinib Versus Osimertinib As First-line Therapy for Patients with EGFR Mutated Locally Advanced or Metastatic Non-small-cell Lung CancerNot yet recruitingNCT06752408Phase 2Report a problem
- Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.RecruitingNCT06574347Phase 2Report a problem
- High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain MetastasesNot yet recruitingNCT06319950Phase 2Report a problem
- TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain MetastasesRecruitingNCT05948813Phase 2Report a problem
- Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)RecruitingNCT05382728Phase 3Report a problem
- Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung CancerTerminatedNCT05493501Phase 3Results postedReport a problem
- A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung CancerActive, not recruitingNCT04487080Phase 3Results postedReport a problem
- Almonertinib Versus Osimertinib in the Patients With EGFR Mutations in Advanced NSCLC With Brain MetastasesStatus unknownNCT04870190Phase 3Report a problem
- A Study to Assess the Effect of Food on the Pharmacokinetics of TY-9591 in Healthy VolunteersCompletedNCT04798638Phase 1Report a problem
- AFAMOSI: Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib in Patients with EGFRmutated/T790M Mutation Negative Nonsquamous NSCLCActive, not recruitingNCT04413201Phase 4Report a problem